Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 11/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KIT | P10721 | 1/20 | 0.30 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24391708 | 0.94 | PDE2A (0.33) | PDE2APIK3CDPOLBKITENPP1 | |
| SCHEMBL24391938 | 0.92 | PDE2A (0.31) | PDE2AKITENPP1 | |
| SCHEMBL24392542 | 0.91 | PDE2A (0.32) | PDE2APIK3CDRIPK1POLBLMNA | |
| SCHEMBL24391879 | 0.91 | PDE2A (0.34) | PDE2APIK3CDJAK3POLBKIT | |
| SCHEMBL24392616 | 0.90 | POLB (0.33) | PDE2APIK3CDPOLB | |
| SCHEMBL24392148 | 0.89 | DPP4 (0.34) | PDE2APIK3CDPOLB | |
| SCHEMBL24392080 | 0.89 | JAK2 (0.33) | PDE2AJAK3POLBKITENPP1 | |
| SCHEMBL24392286 | 0.88 | PDE2A (0.31) | PDE2AKIT | |
| SCHEMBL24391953 | 0.88 | PDE2A (0.31) | PDE2APIK3CDKIT | |
| SCHEMBL24392005 | 0.87 | KIT (0.33) | PDE2AJAK3POLBKITENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022091048-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2022-05-05 | — | — | WO | disclosed |
| US-20220135598-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135598-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, ENPP2 | PDE2A 23/4885PIK3CD 544/4885JAK3 4026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.